Literature DB >> 2128958

Antigen restriction and IgG subclasses among anti-GBM autoantibodies.

M Segelmark1, R Butkowski, J Wieslander.   

Abstract

Thirty-seven sera positive for anti-GBM antibodies (antibodies against the 'Goodpasture antigen' = NC1-domain of collagen IV) in routine analysis were studied for antigen restriction and IgG subclasses. Four different polypeptides, the four alpha-chains (alpha 1, alpha 2, alpha 3 and alpha 4) of human collagen IV NC1, were used as coating in ELISA assays. Autoantibodies were detected with monoclonal antibodies towards human IgG subclasses. All patients had antibodies to the alpha 3 chain, and most patients reacted much more to the alpha 3 peptide than to any of the other three peptides. This shows that the NC1 domain of the alpha 3 chain of collagen IV is the major target for anti-GBM antibodies. A minor group of patients, 6 of 37, showed no antigen restriction and had only moderate titres. It remains to be studied, however, whether they have antibodies to another epitope and a different clinical picture. All four subclasses of IgG antibodies were present, but IgG1 antibodies dominated. A group, consisting of females mainly, had relatively high titres of IgG4 antibodies to the NC1 domain of the alpha 3 chain of collagen IV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2128958     DOI: 10.1093/ndt/5.12.991

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

Review 1.  Basement membranes and autoimmune diseases.

Authors:  Mary H Foster
Journal:  Matrix Biol       Date:  2016-08-02       Impact factor: 11.583

Review 2.  Cutting edge issues in Goodpasture's disease.

Authors:  Andrew L Chan; Samuel Louie; Kevin O Leslie; Maya M Juarez; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 3.  Goodpasture's autoimmune disease - A collagen IV disorder.

Authors:  Vadim Pedchenko; A Richard Kitching; Billy G Hudson
Journal:  Matrix Biol       Date:  2018-05-12       Impact factor: 11.583

4.  Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen.

Authors:  N Turner; P J Mason; R Brown; M Fox; S Povey; A Rees; C D Pusey
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

5.  Proteolysis breaks tolerance toward intact α345(IV) collagen, eliciting novel anti-glomerular basement membrane autoantibodies specific for α345NC1 hexamers.

Authors:  Florina Olaru; Xu-Ping Wang; Wentian Luo; Linna Ge; Jeffrey H Miner; Sandra Kleinau; Xochiquetzal J Geiger; Andrew Wasiluk; Laurence Heidet; A Richard Kitching; Dorin-Bogdan Borza
Journal:  J Immunol       Date:  2013-01-09       Impact factor: 5.422

Review 6.  Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan.

Authors:  Kouichi Hirayama; Kunihiro Yamagata; Masaki Kobayashi; Akio Koyama
Journal:  Clin Exp Nephrol       Date:  2008-04-08       Impact factor: 2.801

7.  Renal injury due to anti-glomerular basement membrane antibody-mediated glomerulonephritis without circulating antibody.

Authors:  F P Schena; Aruna Dash; Huma Fatima; Mandeep Grewal; Claude Galphin; Paisit Paueksakon
Journal:  Clin Kidney J       Date:  2012-10-19

8.  Atypical Noncrescentic Antiglomerular Basement Membrane Disease With Concurrent Thin Basement Membrane Nephropathy.

Authors:  Pooja Singhal; Kevin Yi Mi Ren; Bryan M Curtis; Ian MacPherson; Carmen Avila-Casado
Journal:  Kidney Int Rep       Date:  2018-03-23

9.  A case of aggressive atypical anti-GBM disease complicated by CMV pneumonitis.

Authors:  Barbora Sporinova; Susanna A McRae; Daniel A Muruve; Marvin J Fritzler; Samih H Nasr; Alex C Chin; Hallgrimur Benediktsson
Journal:  BMC Nephrol       Date:  2019-01-31       Impact factor: 2.388

Review 10.  Anti-Glomerular Basement Membrane Disease.

Authors:  Stephen P McAdoo; Charles D Pusey
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-17       Impact factor: 8.237

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.